Skip to content
TriangleGet started
← Aggressive B-Cell Non-Hodgkin Lymphoma

HEALTH PROFESSIONAL · SOURCE READING

Bispecific T-cell engagers

Source: Aggressive B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 12, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary. Independent clinical review is pending.

Context: Treatment of Aggressive, Recurrent B-Cell Non-Hodgkin Lymphoma / Treatment Options for Aggressive, Recurrent B-Cell Non-Hodgkin Lymphoma

Bispecific T-cell engagers (BiTEs) bind to CD20 (or CD19) and to CD3 to direct T cells to eliminate malignant B cells.[39]

Source links and citations

Continue within this section

Epcoritamab →Glofitamab →

Publication references

Read the original reference and check its publication notices.

Preserved source evidence · Independent clinical review pending · Not medical advice